Skip to main content Skip to main navigation menu Skip to site footer

Impact of gender difference towards coronavirus disease 2019 (COVID-19) vaccine antibody response: systematic review

  • Mohammad Edwin Prasetyo ,
  • Gatot Soegiarto ,
  • Laksmi Wulandari ,

Abstract

Introduction: There are several factors contributing to antibody response towards COVID-19 vaccination. Age, infection history, virus mutation, nutritional status, body mass index, gut microbiota, host polymorphism, and immune system have been accounted for variations in antibody development due to COVID-19 vaccination in several studies. Sex differences are also included in the list. Therefore, this study aims to determine the impact of gender differences on antibody development after COVID-19 vaccination on general populations.

Methods: We conducted a systematic review based on the PRISMA statement. Searching for clinical trials was conducted in PubMed, Scopus, EBSCOHost, and ProQuest using selected keywords. Inclusion and exclusion criteria were applied to filter the study. Filtered studies were appraised using The Joanna-Briggs Institute tools for critical appraisal to determine the studies' eligibility for inclusion. Included studies were extracted for study and subjects' characteristics. Study outcomes were analyzed qualitatively and reported.

Results: Eight prospective cohort studies involving 3,381 subjects were included after searching and selection. Appraisal of studies found that studies were considered good enough for inclusion. We found that multiple studies reported higher COVID-19 vaccination antibodies in females compared to males. However, several studies doubted long-term differences due to antibody waning. These doubts were clarified by a study that stated that even though has been adjusted to various demographic factors, females showed significantly higher IgG levels up to 40 weeks. Another finding stated that antibody titer waned much softer in females compared to males.

Conclusion: Antibody towards COVID-19 vaccination was higher in females compared to males as initial response up to several weeks. However, long-term differences should be studied and investigated further.

References

  1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
  2. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process [Internet]. World Health Organization; 2023 [cited 2023 Jun 9]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_29May2023.pdf
  3. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro Surveill. 2021 Jul;26(28):2100563.
  4. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26–35.
  5. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021 Aug;21(8):475–84.
  6. Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. Clin Infect Dis. 2021 Dec 6;73(11):e4223–8.
  7. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021 Feb;27(2):205–11.
  8. Falahi S, Kenarkoohi A. Host factors and vaccine efficacy: Implications for COVID‐19 vaccines. J Med Virol. 2022 Apr;94(4):1330–5.
  9. Cheng ZJ, Xue M, Zheng P, Lyu J, Zhan Z, Hu H, et al. Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines. 2021 Aug 5;9(8):869.
  10. Falahi S, Kenarkoohi A. Sex and gender differences in the outcome of patients with COVID-19. J Med Virol. 2021 Jan;93(1):151–2.
  11. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9–15.
  12. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu Rev Cell Dev Biol. 2017 Oct 6;33:577–99.
  13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71.
  14. The Joanna Briggs Institue critical appraisal tools for use in JBI systematic reviews: checklist for cohort studies [Internet]. The Joanna Briggs Institute; 2017. Available from: http://joannabriggs.org/research/critical-appraisal-tools.html
  15. Anastassopoulou C, Antoni D, Manoussopoulos Y, Stefanou P, Argyropoulou S, Vrioni G, et al. Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods. Fast PE, editor. PLoS ONE. 2022 Apr 29;17(4):e0266958.
  16. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021 Jun 28;12(1):3991.
  17. Heriyanto RS, Kurniawan A, Wijovi F, Halim DA, Jodhinata C, Marcella E, et al. The role of COVID‐19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia. International Journal of Infectious Diseases. 2021 Dec;113:336–8.
  18. Nam SY, Jeon SW, Lee HS, Lim HJ, Lee DW, Yoo SS. Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses. JAMA Netw Open. 2022 May 19;5(5):e2212996.
  19. Ebinger JE, Joung S, Liu Y, Wu M, Weber B, Claggett B, et al. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. BMJ Open. 2022 May;12(5):e059994.
  20. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells A, et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Martinez MA, editor. Microbiol Spectr. 2021 Sep 3;9(1):e00341-21.
  21. Farid E, Herrera-Uribe J, Stevenson NJ. The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine. Front Immunol. 2022 May 30;13:817597.
  22. Chen F, Zhong Y, Li J, Luo J. Dynamic changes of SARS-CoV-2 specific IgM and IgG among population vaccinated with COVID-19 vaccine. Epidemiol Infect. 2022;150:e74.
  23. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. Journal of Allergy and Clinical Immunology. 2019 Apr;143(4):1465–73.
  24. Halsey NA, Griffioen M, Dreskin SC, Dekker CL, Wood R, Sharma D, et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS. Vaccine. 2013 Dec;31(51):6107–12.
  25. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine. 2011 Mar 16;29(13):2349–54.
  26. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019 Mar;41(2):239–49.
  27. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cellular Immunology. 2015 Apr;294(2):87–94.
  28. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008 Sep;8(9):737–44.
  29. Ciarambino T, Barbagelata E, Corbi G, Ambrosino I, Politi C, Lavalle F, et al. Gender differences in vaccine therapy: where are we in COVID-19 pandemic? Monaldi Arch Chest Dis [Internet]. 2021 Apr 8 [cited 2023 Jun 10]; Available from: https://www.monaldi-archives.org/index.php/macd/article/view/1669
  30. Ruggieri A, Anticoli S, D’Ambrosio A, Giordani L, Viora M. The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016;52(2):198–204.
  31. Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. The Lancet Infectious Diseases. 2022 Jul;22(7):1002–10.
  32. Suah JL, Husin M, Tok PSK, Tng BH, Thevananthan T, Low EV, et al. Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. Int J Infect Dis. 2022 Jun;119:69–76.
  33. Intawong K, Chariyalertsak S, Chalom K, Wonghirundecha T, Kowatcharakul W, Thongprachum A, et al. Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand. Miron VD, editor. PLoS ONE. 2023 May 11;18(5):e0284130.

How to Cite

Prasetyo, M. E., Soegiarto, G. ., & Wulandari, L. . (2023). Impact of gender difference towards coronavirus disease 2019 (COVID-19) vaccine antibody response: systematic review. Bali Medical Journal, 13(1), 95–100. https://doi.org/10.15562/bmj.v13i1.4710

HTML
6

Total
4

Share

Search Panel

Mohammad Edwin Prasetyo
Google Scholar
Pubmed
BMJ Journal


Gatot Soegiarto
Google Scholar
Pubmed
BMJ Journal


Laksmi Wulandari
Google Scholar
Pubmed
BMJ Journal